Charles River Labs Names Glenn Coleman CFO with $8.4M Package
Charles River Laboratories International (NYSE: CRL) announced the appointment of Glenn Coleman as Corporate Executive Vice President and Chief Financial Officer, effective April 6, 2026. The preclinical services giant is offering Coleman a compensation package valued at approximately $8.4 million in his first year, signaling the company's commitment to strengthening its financial leadership.
The Change
Coleman, 58, will succeed Michael G. Knell, who has served as interim CFO since September 2025. Knell will continue in his role as Corporate Senior Vice President and Chief Accounting Officer, ensuring a smooth transition period. The appointment ends Charles River's five-month search for permanent financial leadership.
The compensation package reflects the competitive market for experienced healthcare CFOs. Coleman will receive an $800,000 annual base salary, with eligibility for an 85% target bonus (approximately $680,000 for 2026, pro-rated). The company is also providing a one-time new hire cash award of $1.875 million, paid in two installments over his first year, plus equity awards totaling $6.5 million. The equity package includes a $3.5 million new hire grant vesting over four years and an annual award of $3 million split between performance share units (60%) and restricted stock units (40%).
Background
Coleman brings over 30 years of financial and operational management experience, including more than a decade in senior healthcare leadership roles. Most recently, he served as Chief Financial Officer and Chief Administrative Officer at Premier Inc., a $1 billion healthcare services business, a position he has held since 2024.
His healthcare sector expertise runs deep. From 2022 to 2024, Coleman was Executive Vice President and CFO at DENTSPLY SIRONA Inc., a dental technology company. Before that, he spent eight years at Integra Life Sciences Holdings Corporation (2014-2022), where he progressed from CFO to Executive Vice President and Chief Operating Officer. In the COO role at Integra, Coleman demonstrated operational versatility by overseeing not just finance but also clinical, research and development, manufacturing, quality functions, and international operations.
This operational experience sets Coleman apart from traditional finance-only executives. During his tenure at Integra, he managed most of the company's workforce while maintaining financial oversight, a dual capability that could prove valuable as Charles River navigates the complex preclinical services market.
Coleman's foundation includes 25 years in financial management positions at global manufacturing and telecommunications companies, including Curtiss-Wright Corporation and Alcatel-Lucent. He began his career at PricewaterhouseCoopers LLP (formerly Coopers & Lybrand) and holds a Bachelor of Science in Business Administration from Montclair State University. He is also a Certified Public Accountant.
What It Means
The appointment signals Charles River's focus on financial discipline and operational excellence as it competes in the consolidating contract research organization (CRO) market. Coleman's combined CFO-COO experience at Integra Life Sciences suggests he could play a broader strategic role beyond traditional financial management.
The generous compensation package—particularly the $1.875 million signing bonus and $3.5 million in new hire equity—indicates Charles River faced competition in recruiting Coleman. This level of investment in financial leadership typically accompanies periods of strategic transformation or significant growth initiatives.
For investors, Coleman's healthcare sector experience should provide confidence in his ability to navigate the specific challenges facing preclinical CROs, including pricing pressures, biotech funding cycles, and regulatory complexity. His operational background could also help Charles River improve margins through efficiency initiatives, a critical factor as the company faces ongoing cost pressures.
The retention of Michael Knell as Chief Accounting Officer ensures continuity in financial reporting and compliance, while Coleman can focus on strategic financial planning and investor relations. This structure suggests Charles River is building a deeper finance bench to support its global operations.
Coleman's track record at three different public companies provides him with experience in various growth stages and market conditions. At Premier Inc., he managed finances for a services-focused business model. At DENTSPLY SIRONA, he dealt with a product-centric dental technology company. At Integra Life Sciences, he handled both financial and operational responsibilities in the medical device sector. This diverse background positions him well to understand Charles River's hybrid model of services and products across drug discovery and development.
The April start date gives Coleman time for an orderly transition from Premier Inc. while allowing Charles River to close its fiscal year under Knell's interim leadership, ensuring stability through the year-end reporting cycle.
Source: Charles River Laboratories International Inc. Form 8-K filed with the Securities and Exchange Commission on February 18, 2026.